For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a devastating condition, the introduction of Vyndamax and the formulated version represents a true change. These novel therapies protect the transthyretin protein, slowing its damaging build-up and alleviating the burden